logo-loader
RNS
Arix Bioscience PLC

Arix Bioscience Plc - Autolus presents additional AUTO3 data in DLBCL

Arix Bioscience plc

presents additional AUTO3 data in DLBCLAutolus

(LSE:ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company (“Autolus”) (Nasdaq: AUTL), today announced new data highlighting progress on AUTO3, the Autolus CAR T cell therapy being investigated in a Phase 1/2 study in relapsed/refractory diffuse large B cell lymphoma (DLBCL), during the Annual (ASCO) 2020 Virtual Scientific Program beginning ., :LONDON29 May 2020Arix Bioscience plcAutolus Therapeutics plcSociety of Clinical OncologyMay 29

The announcement can be accessed on investor website at and full text of the announcement from is contained below. Management will host a conference call and webcast at / on to discuss the ASCO data. To listen to the webcast and view the accompanying slide deck, please go to:Autolus'Autolushttps://www.autolus.com/investor-relationshttps://www.autolus.com/investor-relations/news-and-events/events8:30 am EDT1:30 pm BST1st June 2020

[ENDS]

For more information on Arix, please contact:Enquiries

, Head of Investor Relations +44 (0)20 7290 1072Arix Bioscience plc


Charlotte Parrycharlotte@arixbioscience.com

Mary Clark, , +44 (0)20 3714 1787Optimum Strategic Communications


Supriya MathurShabnam Bashiroptimum.arix@optimumcomms.com

AboutArix Bioscience plc

is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatmentsfor patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.Arix Bioscience plc

is listed on the Main Market of the . For further information, please visitArix Bioscience plcLondon Stock Exchangewww.arixbioscience.com

presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific ProgramAutolus Therapeutics

– Data continue to show encouraging clinical activity alongside tolerable safety to deliver a potentially highly differentiated product profile –

Conference call and webcast to be held Monday, June 1, 2020 at /8:30 am EDT1:30 pm BST

, May 29, 2020 -- (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced new data highlighting progress on AUTO3, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 study in relapsed/refractory diffuse large B cell lymphoma (DLBCL), during the Annual 2020 (ASCO20) Virtual Scientific Program beginning .LONDONAutolus Therapeutics plc Society of Clinical OncologyMay 29

“Data from the ALEXANDER trial of AUTO3, a CD19/CD22 dual-targeting CAR T product candidate in DLBCL have shown a complete response rate of 63% at the recommended Phase 2 dose range with an excellent safety profile,” said Dr. , Medical Director, Bone Marrow Transplant and Cellular Therapy Program, at St. David’s . “We are encouraged by the current study results and have begun enrollment in an outpatient cohort to assess how this approach may benefit a greater population of DLBCL patients.”Aravind RamakrishnanSarah Cannon Blood Cancer CenterSouth Austin Medical Center

As of the data cut-off date of , 23 patients in the ALEXANDER Phase 1/2 clinical trial of AUTO3 were evaluable for safety and efficacy with a minimum of 28-days follow-up.  AUTO3 was well tolerated, with no patients experiencing dose limiting toxicity, and there were no treatment-related deaths. At a dose of ? 150 x 10 cells across the 2 dosing regimens for pembrolizumab, a single dose of pembrolizumab on day minus 1 (D-1) or three doses of pembrolizumab starting on day 14 (D14), no patient experienced Grade 3 or higher Cytokine Release Syndrome (CRS) and no patient experienced neurotoxicity of any grade. At these doses, 11 out of 16 patients achieved a complete or partial response (ORR=69%), and 9 out of 16 achieved a complete response (CRR=56%) with all 9 complete responses ongoing at a median follow-up of 3 months (range 1-12 months). Additionally, at the recommended Phase 2 dose range of 150 - 450 x 10 cells with pembrolizumab D-1, 6 out of 8 patients achieved a complete response or partial response (ORR=75%), and 5 out of 8 patients achieved a complete response (CRR=63%).April 27, 202066

“We are very pleased with the progression of AUTO3 in DLBCL, combining a high level of complete remissions with a safety profile supportive of outpatient use. We have not seen early relapses from complete remissions and are in the process of confirming the profile at the recommended Phase 2 regimen. Our 20 patient outpatient cohort has started, and the results are expected for the second half of 2020 and will further inform the design of the Phase 2 study,” said Dr. Christian Itin, chairman and chief executive officer of .Autolus

Investor call onMonday June 1, 2020

Management will host a conference call and webcast at 8:30 am EDT/ to discuss the ASCO data. To listen to the webcast and view the accompanying slide presentation, please go to: .1:30 pm BSThttps://www.autolus.com/investor-relations/news-and-events/events

The call may also be accessed by dialing (866) 679-5407 for and callers or (409) 217-8320 for international callers. Please reference conference ID 4880556. After the conference call, a replay will be available for one week. To access the replay, please dial (855) 859-2056 for and callers or (404) 537-3406 for international callers. Please reference conference ID 4880556.U.S.CanadaU.S.Canada

AboutAutolus Therapeutics plc

is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit .AutolusAutoluswww.autolus.com

About AUTO3

AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently being tested in diffuse large B cell lymphoma in the ALEXANDER clinical trial, with a 20-patient cohort that was initiated in Q2 2020 to assess feasibility of treatment in an outpatient setting.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus’ financial condition and results of operations, including its expected cash runway; the development of Autolus’ product candidates, including statements regarding the timing of initiation, completion and the outcome of pre-clinical studies or clinical trials and related preparatory work, and the periods during which the results of the studies and trials will become available; Autolus’ plans to research, develop, manufacture and commercialize its product candidates; the potential for Autolus’ product candidates to be alternatives in the therapeutic areas investigated; and Autolus’ manufacturing capabilities and strategy. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Annual Report on Form 20-F filed with the on as well as discussions of potential risks, uncertainties, and other important factors in future filings with the from time to time. All information in this press release is as of the date of the release, and the company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.Autolus'Securities and Exchange CommissionAutolus'Securities and Exchange CommissionMarch 3, 2020

Contact:

, PhD Vice President, Investor Relations and Corporate Communications +44 (0) 7587 372 619 Lucinda Crabtree


l.crabtree@autolus.com

+44 (0) 7818 430877  Julia Wilson

j.wilson@autolus.com

+1-212-966-3650Susan A. Noonan


S.A. Noonan Communicationssusan@sanoonan.com

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

7 min read